Scale Alert: Aurion Biotech Hires CMO & CQO

🚀 Battle Card

🚀 Battle Card: Aurion Biotech

• Andrew Torres, Ph.D., Chief Manufacturing Officer · 🔗 [LinkedIn](https://www.linkedin.com/company/aurion-biotech/about/)

• Sterling Chung, Chief Regulatory & Quality Officer · 🔗 [LinkedIn](https://www.linkedin.com/company/aurion-biotech/about/)

• This Aurion Biotech sales trigger highlights the urgency to scale manufacturing and regulatory ecosystems ahead of the Phase 3 trial of AURN001 → Source

• Emerging cell therapy manufacturing processes lack scale and global compliance

• Complex multi-regional regulatory hurdles for novel cell therapies

• Primary: CDMO network integration → Scalable, compliant global manufacturing ready for Phase 3

• Expansion: Regulatory submission automation platform → Accelerated RMAT, BTD, and global approvals

• HQ: Seattle, WA & Cambridge, MA & Tokyo

• Employees: ≈ 150

• Rev: ≈ $5 M

• Website: [aurionbiotech.com](https://aurionbiotech.com/)

🤼 Competitive Intel

• Catalent — CDMO
• Unique edge: Proven global cell therapy scale-up
• Evaluated by CMOs & VP Ops for throughput

• Lonza — CDMO
• Unique edge: End-to-end mammalian GMP manufacturing
• Evaluated by Chief Manufacturing Officer for compliance track record

• WuXi AppTec — CDMO
• Unique edge: Integrated discovery-to-commercial services
• Evaluated by VP Ops for turnkey offerings

• Sartorius — Bioprocess equipment
• Unique edge: Modular single-use systems for scale
• Evaluated by Manufacturing teams for flexibility

• Veeva Systems — Regulatory/QMS
• Unique edge: Compliant cloud-based quality management
• Evaluated by Chief Regulatory & Quality Officer for audit readiness

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑BioScaleCDMO❑
OFFER_BRIEF   = ❑Scalable, compliant global cell therapy manufacturing network❑
PROOF_METRIC  = ❑30% faster scale-up❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑punchy❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Andrew
COMPANY     = Aurion Biotech
DEPT        = Manufacturing
SIZE        = ≈12
BOTTLENECK  = lack of scalable cell therapy manufacturing
EVENT       = promotion to Chief Manufacturing Officer
DETAIL      = promotion to Chief Manufacturing Officer
PAIN        = emerging processes lack global scale and compliance
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250930926770&div=41152219
SIM_CO      = Catalent
WIN_METRIC  = 30% faster scale-up
NEXT_SIZE   = ≈30
EMP_EST     = ≈150
REV_EST     = ≈5M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈12-person Manufacturing

Andrew—noticed your Manufacturing team is ≈12.

That’s when lack of scalable cell therapy manufacturing slows growth.

We helped Catalent fix this with Scalable, compliant global cell therapy manufacturing network.

Result: 30% faster scale-up.  
Quick call?

PS—next bottleneck hits ≈30.

DM ≤45 words, TONE:
Saw your post about promotion to Chief Manufacturing Officer — emerging processes lack global scale and compliance.  
Scalable, compliant global cell therapy manufacturing network. 30% faster scale-up.  
Quick chat?